Sequella gets NHI grant for TB drug development
Sequella, a clinical-stage US biopharmaceutical company focused on diseases of epidemic potential, has received a Small Business Innovation Research Phase I Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to fund further preclinical development of the company's novel tuberculosis lead dipiperidine drug compound, SQ609.
The SBIR grant will enable Sequella to perform Investigational New Drug-directed preclinical in vitro and in vivo potency, pharmacology and toxicity studies of SQ609, both as a single agent and in combination with other more established therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze